Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE ACETATE versus SYNALAR HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE ACETATE versus SYNALAR HP.
HYDROCORTISONE ACETATE vs SYNALAR-HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It exerts anti-inflammatory, immunosuppressive, and vasoconstrictive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
Hydrocortisone acetate is typically administered as a topical, intra-articular, intradermal, or rectal preparation. For intra-articular use, adult dose: 5-50 mg (depending on joint size) every 1-2 weeks. For rectal use, 25 mg (one suppository) twice daily or 1 application of foam or enema (10% or 1% respectively) once or twice daily. For intradermal injection, 1-2 mL (25 mg/mL) into lesion every 1-2 weeks. Note: Systemic dosing is not applicable as it is not used for systemic effects due to low bioavailability.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours for endogenous hydrocortisone; with acetate ester, extended to ~2-4 hours due to slower absorption and hydrolysis. Clinical context: Duration of action exceeds half-life due to intracellular receptor binding.
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
Renal: ~80% as metabolites (glucuronide and sulfate conjugates) and <1% unchanged; fecal: <5% via biliary elimination.
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Category D/X
Category C
Corticosteroid
Corticosteroid